Activation of the BTK signalling pathway results in malignant B-cell proliferation and activation, contributing to the development of chronic lymphocytic leukaemia (CLL), MCL, diffuse large B-cell lymphoma (DLBCL), or follicular lymphoma (FL). Here, BTK is linked to diffuse large B-cell lymphoma.